Read More

Sanofi Makes Statement On FTC Challenge To Proposed License Agreement With Maze Therapeutics; Says We Respectfully Disagree With The Action By The FTC Which Also Delays Potential Advancements That Could Impact The Lives Of Patients

Sanofi is disappointed with the Federal Trade Commission's announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics. The agreement, announced on

SNY

Read More

Illumina Submits Form 10 Related To Its Potential Divestiture Of GRAIL To The U.S. SEC, Pursuant To An Order Illumina Received From The European Commission Directing The Company To Divest GRAIL

Illumina, Inc. (NASDAQ:ILMN) has confidentially submitted a draft registration statement on Form 10 related to its potential divestiture of GRAIL to the U.S. Securities and Exchange Commission, pursuant to an order

ILMN